COVID-related revisions to a high-profile Veltassa Phase IIIb trial, and the appointment of a new CEO, ex-GSK executive Abbas Hussain, have punctuated the week at Switzerland’s specialty company, Vifor Pharma Group , which is aiming to build its presence in the cardio-renal space that is also being targeted by other companies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?